Suppr超能文献

利用非有机磷底物分析对氧磷酶-1 (PON1) 状态。

Paraoxonase-1 (PON1) Status Analysis Using Non-Organophosphate Substrates.

机构信息

Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington.

Department of Medicine (Division of Medical Genetics), University of Washington, Seattle, Washington.

出版信息

Curr Protoc. 2021 Jan;1(1):e25. doi: 10.1002/cpz1.25.

Abstract

Human paraoxonase-1 (PON1) is a high-density lipoprotein-associated enzyme with antioxidant, anti-inflammatory, and antiapoptotic roles. The ability of PON1 to hydrolyze specific organophosphate (OP) compounds and prevent accumulation of oxidized lipids in lipoproteins has prompted a large number of studies investigating PON1's role in modulating toxicity and disease. Most of these studies, however, have only focused on PON1 single nucleotide polymorphism analyses and have ignored PON1 activity levels, arguably the most important parameter in determining protection against exposure and disease. We developed a two-substrate activity assay termed "PON1 status" that reveals both the functional PON1 genotype and plasma PON1 activity levels. While our previous studies with PON1 status demonstrated that both PON1 functional genotype and enzymatic activity levels obtained exclusively by determining PON1 status are required for a proper evaluation of PON1's role in modulating OP exposures and risk of disease, the original PON1 status assay requires the use of highly toxic OP metabolites. As many laboratories are not prepared to handle such toxic compounds and the associated waste generated, determination of PON1 status has been limited to rather few studies. Here, we describe a PON1 status protocol that uses non-OP substrates with a resolution equivalent to that of the original PON1 status approach. We have also included useful suggestions to ensure the assays can easily be carried out in any laboratory. The protocols described here will enable a proper examination of the risk of exposure or susceptibility to disease in PON1 epidemiological studies without the need to handle highly toxic substrates. © 2021 Wiley Periodicals LLC. Basic Protocol: Determining PON1 status using non-organophosphate substrates Support Protocol 1: Experimental pathlength determination Support Protocol 2: PON1 DNA genotyping for the Q192R (rs662) polymorphism.

摘要

人对氧磷酶 1(PON1)是一种高密度脂蛋白相关酶,具有抗氧化、抗炎和抗凋亡作用。PON1 水解特定有机磷(OP)化合物的能力以及防止脂蛋白中氧化脂质积累的能力促使大量研究调查 PON1 在调节毒性和疾病中的作用。然而,这些研究大多仅集中在 PON1 单核苷酸多态性分析上,而忽略了 PON1 活性水平,这可能是决定对暴露和疾病的保护最重要的参数。我们开发了一种双底物活性测定法,称为“PON1 状态”,它揭示了功能性 PON1 基因型和血浆 PON1 活性水平。虽然我们之前使用 PON1 状态的研究表明,PON1 功能基因型和仅通过确定 PON1 状态获得的酶活性水平对于正确评估 PON1 在调节 OP 暴露和疾病风险中的作用都是必需的,但原始的 PON1 状态测定法需要使用剧毒的 OP 代谢物。由于许多实验室都没有准备好处理这些有毒化合物及其产生的相关废物,因此 PON1 状态的测定仅限于少数几个研究。在这里,我们描述了一种 PON1 状态方案,该方案使用非 OP 底物,其分辨率与原始 PON1 状态方法相当。我们还包括了一些有用的建议,以确保这些测定可以在任何实验室中轻松进行。这里描述的方案将使 PON1 流行病学研究能够正确检查暴露或对疾病的易感性的风险,而无需处理剧毒底物。 © 2021 威利父子公司。基本方案:使用非有机磷底物确定 PON1 状态 支持方案 1:实验路径长度的确定 支持方案 2:PON1 Q192R(rs662)多态性的 DNA 基因分型

相似文献

1
Paraoxonase-1 (PON1) Status Analysis Using Non-Organophosphate Substrates.
Curr Protoc. 2021 Jan;1(1):e25. doi: 10.1002/cpz1.25.
2
Human PON1, a biomarker of risk of disease and exposure.
Chem Biol Interact. 2010 Sep 6;187(1-3):355-61. doi: 10.1016/j.cbi.2010.03.033. Epub 2010 Mar 23.
3
Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates.
J Toxicol Clin Toxicol. 2003;41(1):37-45. doi: 10.1081/clt-120018269.
4
Paraoxonase-1 and oxidized lipoprotein lipids. The Cardiovascular Risk in Young Finns Study.
Atherosclerosis. 2015 Aug;241(2):502-6. doi: 10.1016/j.atherosclerosis.2015.06.004. Epub 2015 Jun 6.
5
The effect of HDL-bound and free PON1 on copper-induced LDL oxidation.
Chem Biol Interact. 2016 Sep 25;257:141-6. doi: 10.1016/j.cbi.2016.08.007. Epub 2016 Aug 7.
7
The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism.
Chem Biol Interact. 1999 May 14;119-120:429-38. doi: 10.1016/s0009-2797(99)00055-1.
8
Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity.
Toxicology. 2013 May 10;307:115-22. doi: 10.1016/j.tox.2012.07.011. Epub 2012 Jul 31.
9
The role of PON1 and CYP2D6 genes in susceptibility to organophosphorus chronic intoxication in Egyptian patients.
Neurotoxicology. 2016 Mar;53:102-107. doi: 10.1016/j.neuro.2015.12.015. Epub 2015 Dec 23.
10
In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.
BMC Clin Pharmacol. 2009 Nov 17;9:18. doi: 10.1186/1472-6904-9-18.

引用本文的文献

1
Paraoxonase 1: evolution of the enzyme and of its role in protecting against atherosclerosis.
Curr Opin Lipidol. 2024 Aug 1;35(4):171-178. doi: 10.1097/MOL.0000000000000936. Epub 2024 Jun 18.
2
Paraoxonase 1 status is a major Janus-faced component of mild and moderate acute ischemic stroke and consequent disabilities.
Metab Brain Dis. 2023 Aug;38(6):2115-2131. doi: 10.1007/s11011-023-01232-4. Epub 2023 May 19.
3
Paraoxonase 1 and atherosclerosis.
Front Cardiovasc Med. 2023 Feb 16;10:1065967. doi: 10.3389/fcvm.2023.1065967. eCollection 2023.

本文引用的文献

1
Evaluating the link between Paraoxonase-1 levels and Alzheimer's disease development.
Minerva Med. 2019 Jun;110(3):238-250. doi: 10.23736/S0026-4806.18.05875-5. Epub 2018 Oct 11.
2
Paraoxonases-1, -2 and -3: What are their functions?
Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62. doi: 10.1016/j.cbi.2016.05.036. Epub 2016 May 26.
3
Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome.
Clin Biochem. 2013 Dec;46(18):1830-6. doi: 10.1016/j.clinbiochem.2013.08.020. Epub 2013 Sep 10.
4
A functional polymorphism of PON1 interferes with microRNA binding to increase the risk of ischemic stroke and carotid atherosclerosis.
Atherosclerosis. 2013 May;228(1):161-7. doi: 10.1016/j.atherosclerosis.2013.01.036. Epub 2013 Feb 21.
5
Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity.
Toxicology. 2013 May 10;307:115-22. doi: 10.1016/j.tox.2012.07.011. Epub 2012 Jul 31.
6
Long term stability of paraoxonase-1 and high-density lipoprotein in human serum.
Lipids Health Dis. 2012 May 14;11:53. doi: 10.1186/1476-511X-11-53.
7
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.
J Clin Invest. 2011 Jul;121(7):2693-708. doi: 10.1172/JCI42946. Epub 2011 Jun 23.
9
Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on.
Biochem Pharmacol. 2011 Feb 1;81(3):337-44. doi: 10.1016/j.bcp.2010.11.008. Epub 2010 Nov 18.
10
Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques.
Eur J Clin Invest. 2011 Mar;41(3):308-14. doi: 10.1111/j.1365-2362.2010.02411.x. Epub 2010 Oct 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验